Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Ruggiero

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
Clinical and Experimental Dermatology|November 27, 2023
Dupilumab-associated inflammatory arthritis: a literature reviewMaddalena Napolitano, Angelo Ruggiero, Cataldo Patruno
Journal of Community Health|December 1, 2020
Community Knowledge About the Use, Reuse, Disinfection and Disposal of Masks and Filtering Facepiece Respirators: Results of a Study Conducted in a Dermatology Clinic at the University of Naples in ItalyMassimiliano Scalvenzi, Alessia Villani, Angelo Ruggiero
Clinical and Experimental Dermatology|June 3, 2022
Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concernsAngelo Ruggiero, Matteo Megna, Gabriella Fabbrocini, et al.
Clinical and Experimental Dermatology|June 14, 2022
Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on 'Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?'Fabrizio Martora, Claudio Marasca, Gabriella Fabbrocini, et al.
International Journal of Dermatology|June 29, 2022
Reply to: "Usage and perceptions of teledermatology in 2021: a survey of dermatologists" by Ahmad et alAngelo Ruggiero, Alessia Villani, Gabriella Fabbrocini, et al.
The Journal of Dermatological Treatment|April 18, 2020
Biologics for psoriasis patients in the COVID-19 era: more evidence, less fearsMatteo Megna, Angelo Ruggiero, Claudio Marasca, et al.
Journal of the American Academy of Dermatology|March 25, 2021
Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparisonAngelo Ruggiero, Gabriella Fabbrocini, Eleonora Cinelli, et al.
Dermatologic Therapy|March 12, 2020
A case of severe psoriasis in a 84-year-old women successfully treated with ixekizumabLucia Gallo, Angelo Ruggiero, Gabriella Fabbrocini, et al.
Psoriasis (Auckland, N.Z.)|July 21, 2022
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective StudyMatteo Megna, Luca Potestio, Gabriella Fabbrocini, et al.
Dermatologic Therapy|August 8, 2020
Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: Preliminary data of a real-life 16-week retrospective studyMatteo Megna, Gabriella Fabbrocini, Angelo Ruggiero, et al.
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
Clinical and Experimental Dermatology|November 27, 2023
Dupilumab-associated inflammatory arthritis: a literature reviewMaddalena Napolitano, Angelo Ruggiero, Cataldo Patruno
Journal of Community Health|December 1, 2020
Community Knowledge About the Use, Reuse, Disinfection and Disposal of Masks and Filtering Facepiece Respirators: Results of a Study Conducted in a Dermatology Clinic at the University of Naples in ItalyMassimiliano Scalvenzi, Alessia Villani, Angelo Ruggiero
Clinical and Experimental Dermatology|June 3, 2022
Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concernsAngelo Ruggiero, Matteo Megna, Gabriella Fabbrocini, et al.
Clinical and Experimental Dermatology|June 14, 2022
Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on 'Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?'Fabrizio Martora, Claudio Marasca, Gabriella Fabbrocini, et al.
International Journal of Dermatology|June 29, 2022
Reply to: "Usage and perceptions of teledermatology in 2021: a survey of dermatologists" by Ahmad et alAngelo Ruggiero, Alessia Villani, Gabriella Fabbrocini, et al.
The Journal of Dermatological Treatment|April 18, 2020
Biologics for psoriasis patients in the COVID-19 era: more evidence, less fearsMatteo Megna, Angelo Ruggiero, Claudio Marasca, et al.
Journal of the American Academy of Dermatology|March 25, 2021
Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparisonAngelo Ruggiero, Gabriella Fabbrocini, Eleonora Cinelli, et al.
Dermatologic Therapy|March 12, 2020
A case of severe psoriasis in a 84-year-old women successfully treated with ixekizumabLucia Gallo, Angelo Ruggiero, Gabriella Fabbrocini, et al.
Psoriasis (Auckland, N.Z.)|July 21, 2022
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective StudyMatteo Megna, Luca Potestio, Gabriella Fabbrocini, et al.
Dermatologic Therapy|August 8, 2020
Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: Preliminary data of a real-life 16-week retrospective studyMatteo Megna, Gabriella Fabbrocini, Angelo Ruggiero, et al.
Pageof 14